AGIO · CIK 0001439222
What Agios Pharmaceuticals, Inc. told the SEC could break it.
Agios's register is defined by how concentrated its commercial business is. Its revenue comes almost entirely from one drug, PYRUKYND, sold through a handful of US specialty distributors — and a single customer accounted for 89% of consolidated revenue in 2025 (95% and 96% the prior two years) and 55% of product receivables, so a loss, payment failure or channel change at that one distributor would severely disrupt revenue. It owns no manufacturing, relying entirely on third-party contract manufacturers for commercial supply of PYRUKYND and its newly launched AQVESME, with no in-house fallback if one fails. As a high-priced rare-disease franchise, it is also exposed to US drug-pricing policy, notably the Inflation Reduction Act's expanding Medicare price-negotiation program.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Extreme single-customer concentration — one (unnamed) U.S. specialty distributor = 89% of consolidated revenue (95%/96% in 2024/2023)high
Agios's commercial revenue comes almost entirely from PYRUKYND (mitapivat) sold to a limited number of U.S. specialty distributors and specialty pharmacies (plus small ex-US distributors Avanzanite and NewBridge). The concentration is extreme: one customer accounted for 89% of consolidated revenue in 2025 (95% and 96% in 2024 and 2023), and 55% of product accounts receivable in 2025. Loss of, a payment failure by, or a channel change at this single distributor would severely disrupt revenue and collections. The customer is not named, so this is a concentration risk rather than a named edge. A very high single-customer concentration on a single-product franchise.
“One Customer accounted for 89 %, 95 % and 96 % of our consolidated revenues for the years ended December 31, 2025, 2024 and 2023”
SEC filing →As of 2026
Regulatory & policy
- IRA Medicare drug-price negotiation (expanding cycles) + Part D coverage-gap 70% manufacturer discount on its branded productsmedium
Agios's branded products (PYRUKYND, AQVESME) are exposed to U.S. drug-pricing policy: the Inflation Reduction Act's Medicare drug-price-negotiation program is live and expanding (first 10 negotiated prices effective Jan 1, 2026; CMS selected 15 additional Part D drugs on Jan 17, 2025 for the second cycle effective 2027), alongside the 70% manufacturer point-of-sale discount on brand drugs in the Part D coverage gap and 340B expansion. As a rare-disease, high-priced franchise, future inclusion or broader pricing pressure (notwithstanding possible orphan exclusions) would compress net realized price. A specific, expanding drug-pricing policy exposure.
“On January 17, 2025, CMS announced the selection of 15 additional drugs covered by Medicare Part D for the second cycle of negotiations.”
Supplier concentration
- Full reliance on third-party manufacturers (CMOs) for commercial supply of PYRUKYND and AQVESME (and clinical supply)medium
Agios owns no manufacturing: it relies, and expects to continue relying, on third parties for the manufacture of its product candidates for preclinical/clinical testing and for commercial supply of PYRUKYND and the newly launched AQVESME (and any future approved product). A performance failure, cGMP/quality problem, capacity constraint, or insolvency at a key contract manufacturer would interrupt supply of its only commercial products, with no in-house fallback. The manufacturers are not named, so this is a contract-manufacturing/sole-source dependence rather than a named edge. A material outsourced-manufacturing supply dependence.
“the manufacture of our product candidates for preclinical and clinical testing and for commercial supply of PYRUKYND® and AQVESME™”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch